Buscar en
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Toda la web
Inicio Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) Glycolytic activity in breast cancer using 18F-FDG PET/CT as prognostic predicto...
Journal Information
Vol. 35. Issue 3.
Pages 152-158 (May - June 2016)
Share
Share
Download PDF
More article options
Visits
3
Vol. 35. Issue 3.
Pages 152-158 (May - June 2016)
Original article
Glycolytic activity in breast cancer using 18F-FDG PET/CT as prognostic predictor: A molecular phenotype approach
Actividad glicolítica en el cancer de mama mediante 18F-FDG PET/TC como predictor pronóstico: aproximación del fenotipo molecular
Visits
3
A.M. Garcia Vicentea,
Corresponding author
angarvice@yahoo.es

Corresponding author.
, A. Soriano Castrejóna, M. Amo-Salasb, J.F. Lopez Fidalgob, M.M. Muñoz Sanchezc, R. Alvarez Cabellosd, R. Espinosa Aunione, V. Muñoz Maderof
a Nuclear Medicine Department, University General Hospital, Ciudad Real, Spain
b Department of Mathematics, University of Castilla-La Mancha, Ciudad Real, Spain
c Oncology Department, Virgen de la Luz Hospital, Cuenca, Spain
d Oncology Department, Virgen de la Salud Hospital, Toledo, Spain
e Oncology Department, La Mancha Centro Hospital, Alcázar de San Juan, Ciudad Real, Spain
f Surgery Department, Gómez Ulla Hospital, Madrid, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (3)
Show moreShow less
Tables (6)
Table 1. Patient's tumor characteristics.
Table 2. Relation of age and metabolical variables with respect to molecular phenotypes.
Table 3. Relation of prognostic variables with molecular phenotypes.
Table 4. Distribution of age and metabolical variables with respect to risk phenotype classification.
Table 5. Relation between prognostic variables and risk phenotype classification.
Table 6. Relation of histological lymph node status with patient age and metabolic characteristics.
Show moreShow less
Abstract
Aim

To explore the relationship between basal 18F-FDG uptake in breast tumors and survival in patients with breast cancer (BC) using a molecular phenotype approach.

Material and Methods

This prospective and multicentre study included 193 women diagnosed with BC. All patients underwent an 18F-FDG PET/CT prior to treatment. Maximum standardized uptake value (SUVmax) in tumor (T), lymph nodes (N), and the N/T index was obtained in all the cases. Metabolic stage was established.

As regards biological prognostic parameters, tumors were classified into molecular sub-types and risk categories. Overall survival (OS) and disease free survival (DFS) were obtained.

An analysis was performed on the relationship between semi-quantitative metabolic parameters with molecular phenotypes and risk categories. The effect of molecular sub-type and risk categories in prognosis was analyzed using Kaplan–Meier and univariate and multivariate tests.

Results

Statistical differences were found in both SUVT and SUVN, according to the molecular sub-types and risk classifications, with higher semi-quantitative values in more biologically aggressive tumors. No statistical differences were observed with respect to the N/T index.

Kaplan–Meier analysis revealed that risk categories were significantly related to DFS and OS. In the multivariate analysis, metabolic stage and risk phenotype showed a significant association with DFS.

Conclusion

High-risk phenotype category showed a worst prognosis with respect to the other categories with higher SUVmax in primary tumor and lymph nodes.

Keywords:
Breast cancer
18F-FDG PET/CT
Molecular phenotypes
Prognosis
Disease free status
Disease free survival
Overall survival
Resumen
Objetivo

Analizar la relación entre la captación basal de 18F-FDG en tumores mamarios y la supervivencia en pacientes con cancer de mama (CM) bajo la aproximación del fenotipo molecular.

Material y métodos

Este estudio prospectivo y multicentrico incluyó 193 mujeres diagnosticadas de CM. Todas las pacientes fueron sometidas a una 18F-FDG PET/TC previa al tratamiento. Se obtuvo el SUVmax en el tumor (T), ganglios linfáticos (N) así como el índice N/T en todos los casos. Además se determinó el estadio metabólico.

Atendiendo a los factores biológicos pronósticos, los tumores fueron clasificados en subtipos moleculares y categorias de riesgo. Se obtuvo tanto la supervivencia global (SG) como la supervivencia libre de enfermedad (SLE).

Se estudió la relación entre los parámetros metabólicos semicuantitativos con los fenotipos moleculares y las categorías de riesgo. Se analizó el efecto del subtipo molecular y las categorías de riesgo en el pronóstico mediante análisis de Kaplan–Meier y test uni y multivariantes.

Resultados

Se encontraron diferencias estadísticamente significativas en tanto el SUVT como el SUVN, deacuerdo a los fenotipos moleculares y las categorías de riesgo, con valores mayores en los tumores biológicamente más agresivos. No se observaron diferencias con respecto al índice N/T.

El análisis de Kaplan–Meier reveló que las categorías de riesgo se relacionaron de forma significativa con la SG y SLE. En el análisis multivariante, el estadio metabólico y la categoría de riesgo mostraron asociación significativa con la SLE.

Conclusion

La categoría de alto riesgo manifestó un peor pronóstico con respecto a las otras categorías, con mayores valores de SUVmax tanto en el tumor primario como en ganglios linfáticos.

Palabras clave:
Cáncer de mama
18F-FDG PET/TC
Fenotipos moleculares
Pronóstico
Estado libre de enfermedad
Supervivencia libre de enfermedad
Supervivencia global

Article

These are the options to access the full texts of the publication Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos